Section Arrow
ASND.NASDAQ
- Ascendis Pharma A/S
Quotes are at least 15-min delayed:2025/07/20 19:10 EDT
Regular Hours
Last
 169.9
-7.3 (-4.12%)
Day High 
179.9567 
Prev. Close
177.2 
1-M High
180.78 
Volume 
617.70K 
Bid
167
Ask
175
Day Low
169.52 
Open
177.86 
1-M Low
166.84 
Market Cap 
10.72B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 174.77 
20-SMA 174.3 
50-SMA 168.76 
52-W High 183 
52-W Low 111.09 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.81/2.60
Enterprise Value
11.08B
Balance Sheet
Book Value Per Share
-3.66
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
363.64M
Operating Revenue Per Share
2.66
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed:2025/07/20 19:10 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.